Streetbeat News

Earnings

BNOX

Bionomics shares surged following the announcement of positive results from the Phase 2b ATTUNE trial of BNC210 for treating post-traumatic stress disorder.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:09 am

LU

Lufax Holding (NYSE:LU) reported Q4 losses of $(0.21) per share, missing the $(0.02) estimate by 950%, and a 5% decrease from last year's $(0.20) per share. Sales were $965.76M, missing the $1.05B estimate by 8.02%, and a 45.93% decrease from last year's $1.79B.

Portfolio Pulse from dijoy@benzinga.com

March 21, 2024 | 10:06 am

RMTI

Rockwell Medical forecasts FY2024 sales to be between $84M-$88M, below the consensus estimate of $98.01M. The company anticipates a gross margin of 14%-16% and expects to achieve profitability on an adjusted EBITDA basis for the full year 2024.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:06 am

BZUN

Baozun (NASDAQ:BZUN) reported Q4 earnings with an EPS of $0.07, missing estimates by -56%, and revenue up $21.44 million YOY. Last quarter, a beat on EPS was followed by a 10% drop in share price.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 10:05 am

RMTI

Rockwell Medical (NASDAQ:RMTI) reported Q4 earnings of $0.02 per share, surpassing the $(0.07) estimate, marking a 166.67% increase from last year. However, their $22.10M sales missed the $22.63M estimate, though it's a 14.43% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:03 am

BZUN

Baozun reported Q4 adjusted earnings per ADS of $0.07, missing the consensus estimate of $0.16 by 56.25%, and a 79.41% decrease from last year's $0.34. However, their quarterly sales of $391.61M exceeded estimates by 2.47% and grew 5.79% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:03 am

XFOR

X4 Pharmaceuticals (NASDAQ:XFOR) reported Q4 earnings with losses of $(0.10) per share, surpassing the analyst consensus estimate of $(0.15) by 33.33%. This represents a 65.52% improvement over the previous year's losses of $(0.29) per share.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:02 am

FENC

Fennec Pharmaceuticals reported Q4 earnings with a loss of $(0.10) per share, missing the $(0.02) estimate by 400%, but showed a 61.54% improvement from last year. Sales reached $9.73M, exceeding the $8.67M estimate by 12.28% and marking a 534.20% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:02 am

ARKG

ARKK

MRNA

PFE

Cathie Wood's Ark Invest has significantly increased its stake in Moderna, Inc. (MRNA), doubling its holdings since the fourth quarter, as indicated by recent purchases through its ARK Innovation ETF (ARKK) and Ark Genomic Revolution ETF (ARKG). This move comes as Moderna diversifies its product pipeline beyond its COVID-19 vaccine, Spikevax, and reports strong revenue figures. Meanwhile, Ark has sold off its shares in Pfizer, Inc. (PFE), a rival COVID-19 vaccine maker. Moderna's stock has seen a modest year-to-date gain, lagging behind the broader market, but analysts see a potential upside.

Portfolio Pulse from Shanthi Rexaline

March 21, 2024 | 10:00 am

GOOG

GOOGL

RDDT

Wedbush's Dan Ives highlighted the upcoming Reddit Inc. IPO as a potential 'watershed' moment for the tech industry, emphasizing its engagement, advertising potential, and AI data generation capabilities. Ives predicts Reddit will hit $1 billion in revenue next year. The IPO is drawing attention for its potential impact on tech and AI, with Reddit having secured a $60 million deal with Alphabet Inc. ahead of its IPO, which could be priced at the top range of $31 to $34 per share.

Portfolio Pulse from Rounak Jain

March 21, 2024 | 9:38 am